 |
Prospector
Profile
07.1173
|
| |
| Herborium Group, Inc. |
NAICS |
325411 |
| 3 Oak Street
Teaneck, NJ 07666 |
Description |
Health Supplements Mfg. |
| (201) 836-2424 |
Employees |
1 |
| http://www.herborium.com/ |
Revenue |
(mil) |
0.8270 |
| |
Income |
(mil) |
-0.3390 |
| |
Assets |
(mil) |
0.1180 |
| |
Liability |
(mil) |
0.8410 |
| |
(for the year ended 2006-11-30) |
| |
|
Category:
Loss/Deficit
|
| |
|
Event:
Herborium Group, Inc. reported a net loss of $142,383 on revenues of $197,319 for the three months ended May 31, 2007, compared to a net loss of $80,633 on revenues of $223,771 during the same period last year. The Company has an accumulated deficit of $1,348,500 and stockholder's deficit of $866,250 as of May 31, 2007. It also has strained liquidity with $89,306 in total current assets available to pay $990,574 in total current liabilities.
|
| |
|
Intellectual Property:
All of the Company's existing and pipeline products are presently protected as trade secrets. Some of its products may qualify for patent protection that will involve the ingredients, ratios of ingredients, and specific fractions for extracts of ingredients and/or an extraction process. The Company believes trade secrets are the best method at this time to protect herbal based products. [SEC Filing 10-KSB 03-30-07]
|
| |
|
Description:
The Company focuses on developing, licensing, and marketing proprietary, botanical based healthcare products to consumers and healthcare professionals.
|
| |
|
Officers:
Dr. Agnes P. Olszewski (Pres., CEO, CFO & Dir.); Dr. James P. Gilligan (Dir.); Max G. Ansbacher (Dir.); Wayne I. Danson (Dir.)
|
| |
|
Auditor:
Berenson LLP
|
| |
|
Securities:
Common Stock-Symbol HBRM.OB; OTC BB;
114,067,080 common shares outstanding as of July 6, 2007.
|
| |
| |
| |
| return to main page |
|
|
